Exocrine Pancreatic Insufficiency Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Description
Growth Factors of Exocrine Pancreatic Insufficiency Therapeutics Market
The global exocrine pancreatic insufficiency therapeutics market size was valued at USD 1.49 billion in 2018 and is projected tgrow tUSD 3.36 billion by 2032, exhibiting a CAGR of 5.7% during the forecast period of 2019-2032.
The COVID-19 pandemic notably impacted the market for treating Exocrine Pancreatic Insufficiency (EPI). It precipitated extreme problems for healthcare offerings and disrupted supply chains. Many clinical techniques have been placed on maintenance, and getting inthealthcare facilities has become challenging. This situation made diagnosing and dealing with EPI well difficult, resulting in a temporary slowdown in exocrine pancreatic insufficiency therapeutics market growth.
The call for exocrine pancreatic insufficiency (EPI) treatments is developing because more people are growing EPI because of chronic health troubles like cystic fibrosis, diabetes, and pancreatic sicknesses. Better awareness and advances in diagnostic equipment assist in discovering EPI in advance, which has led ta better need for effective remedies.
The marketplace for treating Exocrine Pancreatic Insufficiency is growing because more humans are getting persistent pancreatitis and cystic fibrosis. This growth is pushed by improving stronger and more focused enzyme substitute treatments (ERT), which are extra powerful and feature fewer aspect results. These enhancements boost the global exocrine pancreatic insufficiency therapeutics market share for those treatments. Additionally, higher drug delivery methods, like enteric-coated drugs and microsphere formulations, beautify how enzymes are brought and help sufferers persist with their treatment plans without problems.
Comprehensive Analysis of Exocrine Pancreatic Insufficiency Therapeutics Market
The Exocrine Pancreatic Insufficiency (EPI) therapeutics market is segmented based on therapy and distribution channels. In phrases of remedy, the marketplace is divided intpancreatic enzyme substitute therapy (PERT) and dietary therapy. The PERT segment is anticipated tdominate and develop at the very best charge because of its established efficacy and potency in remedy. Nutritional remedies, while preserving a smaller marketplace percentage, remain critical in coping with EPI tprevent headaches and improve the consequences for the affected person. Regarding distribution channels, sanatorium pharmacies are predicted tpreserve the most significant proportion as medications are usually prescribed in scientific settings. Retail pharmacies and drug stores are projected tmaintain the second one-biggest percentage, with the boom driven by the increasing use of online pharmacy offerings for prescription refills.
The Asia Pacific region led the exocrine pancreatic insufficiency therapeutics market by benefitting a size of USD 1.18 billion in 2018 due tthe speedy adoption of superior therapeutics and ongoing research and improvement efforts across the area; the market increase is expected tbe driven.
The leading players in the Exocrine Pancreatic Insufficiency (EPI) therapeutics market significantly influence its growth trajectory and set industry standards. These key players, including AbbVie Inc. (U.S.), Janssen Pharmaceuticals, Inc. (Belgium), Allergan (Ireland), AzurRx (U.S.), CHIESI Farmaceutici S.p.A. (Italy), and other prominent players, contribute ta competitive landscape, driving innovation and advancements in the treatment of EPI. Their strategic efforts in research, development, and product commercialization continue tshape market growth and improve patient therapeutic options.
In May 2018, VIVUS, Inc. Declared that it had acquired the product rights for PANCREAZE, a pancreatic enzyme coaching containing pancrelipase, derived from porcine pancreatic glands, from Janssen Pharmaceuticals tdeal with Exocrine Pancreatic Insufficiency (EPI).
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2015-2026
Base Year 2018
Forecast Period 2019-2026
Historical Period 2015-2017
Unit Value (USD billion)
Segmentation By Therapy
Pancreatic Enzyme Replacement Therapy (PERT)
Creon
Zenpep
Others
Nutritional Therapy
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
By Geography
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
Rest of the World
The global exocrine pancreatic insufficiency therapeutics market size was valued at USD 1.49 billion in 2018 and is projected tgrow tUSD 3.36 billion by 2032, exhibiting a CAGR of 5.7% during the forecast period of 2019-2032.
The COVID-19 pandemic notably impacted the market for treating Exocrine Pancreatic Insufficiency (EPI). It precipitated extreme problems for healthcare offerings and disrupted supply chains. Many clinical techniques have been placed on maintenance, and getting inthealthcare facilities has become challenging. This situation made diagnosing and dealing with EPI well difficult, resulting in a temporary slowdown in exocrine pancreatic insufficiency therapeutics market growth.
The call for exocrine pancreatic insufficiency (EPI) treatments is developing because more people are growing EPI because of chronic health troubles like cystic fibrosis, diabetes, and pancreatic sicknesses. Better awareness and advances in diagnostic equipment assist in discovering EPI in advance, which has led ta better need for effective remedies.
The marketplace for treating Exocrine Pancreatic Insufficiency is growing because more humans are getting persistent pancreatitis and cystic fibrosis. This growth is pushed by improving stronger and more focused enzyme substitute treatments (ERT), which are extra powerful and feature fewer aspect results. These enhancements boost the global exocrine pancreatic insufficiency therapeutics market share for those treatments. Additionally, higher drug delivery methods, like enteric-coated drugs and microsphere formulations, beautify how enzymes are brought and help sufferers persist with their treatment plans without problems.
Comprehensive Analysis of Exocrine Pancreatic Insufficiency Therapeutics Market
The Exocrine Pancreatic Insufficiency (EPI) therapeutics market is segmented based on therapy and distribution channels. In phrases of remedy, the marketplace is divided intpancreatic enzyme substitute therapy (PERT) and dietary therapy. The PERT segment is anticipated tdominate and develop at the very best charge because of its established efficacy and potency in remedy. Nutritional remedies, while preserving a smaller marketplace percentage, remain critical in coping with EPI tprevent headaches and improve the consequences for the affected person. Regarding distribution channels, sanatorium pharmacies are predicted tpreserve the most significant proportion as medications are usually prescribed in scientific settings. Retail pharmacies and drug stores are projected tmaintain the second one-biggest percentage, with the boom driven by the increasing use of online pharmacy offerings for prescription refills.
The Asia Pacific region led the exocrine pancreatic insufficiency therapeutics market by benefitting a size of USD 1.18 billion in 2018 due tthe speedy adoption of superior therapeutics and ongoing research and improvement efforts across the area; the market increase is expected tbe driven.
The leading players in the Exocrine Pancreatic Insufficiency (EPI) therapeutics market significantly influence its growth trajectory and set industry standards. These key players, including AbbVie Inc. (U.S.), Janssen Pharmaceuticals, Inc. (Belgium), Allergan (Ireland), AzurRx (U.S.), CHIESI Farmaceutici S.p.A. (Italy), and other prominent players, contribute ta competitive landscape, driving innovation and advancements in the treatment of EPI. Their strategic efforts in research, development, and product commercialization continue tshape market growth and improve patient therapeutic options.
In May 2018, VIVUS, Inc. Declared that it had acquired the product rights for PANCREAZE, a pancreatic enzyme coaching containing pancrelipase, derived from porcine pancreatic glands, from Janssen Pharmaceuticals tdeal with Exocrine Pancreatic Insufficiency (EPI).
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2015-2026
Base Year 2018
Forecast Period 2019-2026
Historical Period 2015-2017
Unit Value (USD billion)
Segmentation By Therapy
Pancreatic Enzyme Replacement Therapy (PERT)
Creon
Zenpep
Others
Nutritional Therapy
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Drug Stores
Others
By Geography
North America (U.S. and Canada)
Europe (U.K., Germany, France, Italy, Spain, and Rest of Europe)
Asia Pacific (Japan, China, India, Australia, and Rest of Asia Pacific)
Rest of the World
Table of Contents
128 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 4. Key Insights
- 4.1. Prevalence of Major Disorders Associated With Exocrine Pancreatic Insufficiency
- 4.2. Pipeline Analysis
- 4.3. Recent Industry Developments Such as Mergers, Partnerships & Acquisitions
- 4.4. Regulatory Scenario
- 4.5. New Product Launches
- 5. Global Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Therapy
- 5.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 5.2.1.1. Creon
- 5.2.1.2. Zenpep
- 5.2.1.3. Others
- 5.2.2. Nutritional Therapy
- 5.3. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.3.1. Hospital Pharmacies
- 5.3.2. Retail Pharmacies & Drug Stores
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Country
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- 6.1. Key Findings / Summary
- 6.2. Market Analysis – By Therapy
- 6.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 6.2.1.1. Creon
- 6.2.1.2. Zenpep
- 6.2.1.3. Others
- 6.2.2. Nutritional Therapy
- 6.3. Market Analysis – By Distribution Channel
- 6.3.1. Hospital Pharmacies
- 6.3.2. Retail Pharmacies & Drug Stores
- 6.3.3. Others
- 6.4. Market Analysis – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- 7.1. Key Findings / Summary
- 7.2. Market Analysis – By Therapy
- 7.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 7.2.1.1. Creon
- 7.2.1.2. Zenpep
- 7.2.1.3. Others
- 7.2.2. Nutritional Therapy
- 7.3. Market Analysis – By Distribution Channel
- 7.3.1. Hospital Pharmacies
- 7.3.2. Retail Pharmacies & Drug Stores
- 7.3.3. Others
- 7.4. Market Analysis – By Country
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Rest of Europe
- 8. Asia Pacific Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- 8.1. Key Findings / Summary
- 8.2. Market Analysis – By Therapy
- 8.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 8.2.1.1. Creon
- 8.2.1.2. Zenpep
- 8.2.1.3. Others
- 8.2.2. Nutritional Therapy
- 8.3. Market Analysis – By Distribution Channel
- 8.3.1. Hospital Pharmacies
- 8.3.2. Retail Pharmacies & Drug Stores
- 8.3.3. Others
- 8.4. Market Analysis – By Country
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Rest of Asia Pacific
- 9. Rest of the World Exocrine Pancreatic Insufficiency Therapeutics Market Analysis, Insights and Forecast, 2015-2026
- 9.1. Key Findings / Summary
- 9.2. Market Analysis – By Therapy
- 9.2.1. Pancreatic Enzyme Replacement Therapy (PERT)
- 9.2.1.1. Creon
- 9.2.1.2. Zenpep
- 9.2.1.3. Others
- 9.2.2. Nutritional Therapy
- 9.3. Market Analysis – By Distribution Channel
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies & Drug Stores
- 9.3.3. Others
- 9.4. Market Analysis – By Country
- 10. Competitive Analysis
- 10.1. Key Industry Developments
- 10.2. Global Market Share Analysis (2018)
- 10.3. Competition Dashboard
- 10.4. Comparative Analysis – Major Players
- 10.5. Company Profiles
- 10.5.1. AbbVie Inc.
- 10.5.1.1. Overview,
- 10.5.1.2. Products & services,
- 10.5.1.3. SWOT analysis,
- 10.5.1.4. Recent developments,
- 10.5.1.5. strategies,
- 10.5.1.6. financials (based on availability)
- 10.5.2. Janssen Pharmaceuticals, Inc.
- 10.5.2.1. Overview,
- 10.5.2.2. Products & services,
- 10.5.2.3. SWOT analysis,
- 10.5.2.4. Recent developments,
- 10.5.2.5. strategies,
- 10.5.2.6. financials (based on availability)
- 10.5.3. Allergan
- 10.5.3.1. Overview,
- 10.5.3.2. Products & services,
- 10.5.3.3. SWOT analysis,
- 10.5.3.4. Recent developments,
- 10.5.3.5. strategies,
- 10.5.3.6. financials (based on availability)
- 10.5.4. AzurRx
- 10.5.4.1. Overview,
- 10.5.4.2. Products & services,
- 10.5.4.3. SWOT analysis,
- 10.5.4.4. Recent developments,
- 10.5.4.5. strategies,
- 10.5.4.6. financials (based on availability)
- 10.5.5. CHIESI Farmaceutici S.p.A.
- 10.5.5.1. Overview,
- 10.5.5.2. Products & services,
- 10.5.5.3. SWOT analysis,
- 10.5.5.4. Recent developments,
- 10.5.5.5. strategies,
- 10.5.5.6. financials (based on availability)
- 10.5.6. Other Prominent Players
- 10.5.6.1. Overview,
- 10.5.6.2. Products & services,
- 10.5.6.3. SWOT analysis,
- 10.5.6.4. Recent developments,
- 10.5.6.5. strategies,
- 10.5.6.6. financials (based on availability) "
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
